T cell receptor and B cell receptor (TCR (T cell receptor), BCR (B cell receptor))

T cell receptors and B cell receptors are transmembrane glycoproteins found on the surface of T and B lymphocytes, respectively, and play crucial roles in the adaptive immune system's ability to detect and respond to pathogens. The **T cell receptor** is typically composed of an alpha and a beta chain (or less commonly gamma and delta), forming a complex with CD3 invariant chains that signal upon antigen recognition[1][3][7][8]. TCRs recognize short peptide antigens presented by major histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells. The **B cell receptor** is a membrane-bound immunoglobulin, comprising two heavy and two light chains, and is capable of directly binding intact antigens (proteins, lipids, polysaccharides)[1][7]. Both receptor types have remarkable antigen-binding diversity driven by genetic recombination mechanisms (V(D)J recombination for TCR; V(D)J and somatic hypermutation for BCR), which is fundamental for clonal selection and adaptive immunity[3][7]. Upon antigen engagement, each receptor initiates a cascade of signal transduction pathways that activate, differentiate, and proliferate lymphocyte populations essential for immune defense. Despite sharing core structural features and biological roles in antigen recognition, T cell receptors and B cell receptors differ in the specifics of antigen recognition, associated signaling proteins, and downstream functions. Therapeutically, both receptor families are indirectly targeted for immune modulation in cancer, autoimmune disease, and infection, but the entry provided is not a standard canonical form as both represent distinct molecular entities[7][1].

Other names

TCR (for T cell receptor)BCR (for B cell receptor)T cell antigen receptorB cell antigen receptorT lymphocyte antigen receptorMembrane immunoglobulin (mIg, for BCR)Immunoglobulin receptor (for BCR)

Inhibition of receptor-mediated signaling (e.g., via kinase inhibition for BCR/TCR pathways) Blockade of antigen recognition Enhancement of cytotoxic or helper T cell responses (through checkpoint inhibition) Targeted cytolysis via antibody-Fc mediated mechanisms